Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trastuzumab Deruxtecan in HER2-Mutated Solid Tumors
NCT04639219Phase 2Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Dec 2020
- Primary completion
- Jan 2023
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 9
01
Overview
Phase 2, open-label, single-arm trial of trastuzumab deruxtecan in solid tumor, sponsored by AstraZeneca. Primary endpoint: Confirmed Overall Response Rate up to 24 months. Started Dec 2020; status: active, not recruiting.
02
Drugs
trastuzumab deruxtecan
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04639219.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04639219.